Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells $65,248.38 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder James C. Czirr sold 21,323 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Galectin Therapeutics Price Performance

Shares of GALT traded up $0.02 during midday trading on Thursday, reaching $3.31. The stock had a trading volume of 49,903 shares, compared to its average volume of 129,047. The company’s 50-day moving average is $2.51 and its 200 day moving average is $2.09. Galectin Therapeutics Inc. has a 12-month low of $1.28 and a 12-month high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. Equities analysts predict that Galectin Therapeutics Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. D.A. Davidson & CO. raised its holdings in Galectin Therapeutics by 15.2% in the third quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock worth $73,000 after purchasing an additional 5,000 shares in the last quarter. Retirement Guys Formula LLC boosted its position in shares of Galectin Therapeutics by 87.0% during the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock valued at $36,000 after buying an additional 10,000 shares during the last quarter. Beacon Capital Management LLC raised its holdings in shares of Galectin Therapeutics by 89.6% during the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock valued at $40,000 after purchasing an additional 11,300 shares during the last quarter. AE Wealth Management LLC lifted its holdings in shares of Galectin Therapeutics by 72.7% during the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock valued at $52,000 after buying an additional 11,300 shares during the period. Finally, Solutions 4 Wealth Ltd bought a new position in Galectin Therapeutics in the fourth quarter valued at about $60,000. Institutional investors own 11.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GALT. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.